The results showed that salirasib treatment of SSc fibroblasts leads to reduced differentiation of fibroblasts into α‐SMA‐positive myofibroblasts and decreased ACTA2 gene expression (p = 0.012) (Figure 4f–j). The gene discussed is ACTA2; the disease is systemic sclerosis.